Help us make childhood cancer universally survivable.
By giving monthly, you directly support our continued research into discovering effective and less toxic treatments for childhood cancer.
Support Our Lab
Our team of scientists and engineers are on a mission...
We are a nonprofit biotech lab on a mission to make childhood cancer universally survivable. Every year, the FDA approves on average 12 drugs to treat adult cancer, but has only approved 8 drugs to treat childhood cancer since 1978.
giving back childhood for
In 2014, Megan Bugg was diagnosed with stage 4 Alveolar Rhabdomyosarcoma (ARMS), the most aggressive form of Rhabdomyosarcoma, affecting the soft tissue most commonly in children, adolescents and young adults. ARMS has received very little clinical research to date. In fact, no primary drug approvals for RMS have ever occurred and only 8 drugs have received FDA approval for ANY childhood cancer since 1978. Contrast that with the average 12 cancer drugs approved each year for adults. So in the spring of 2020 Megan, along with her team of supporters, a.k.a. Team Megan Bugg – set
In the Press
Beaverton lab identifies drug that turns off key gene in deadly childhood muscle cancer
The Children's Cancer Therapy Development Institute is studying how a breast cancer drug candidate could impact children with an aggressive tumor in the soft muscle.
Scientists And Parents Band Together To Research Cures For Rare Childhood Cancer
Small patient numbers mean there's less motivation to allocate resources to study the diseases and develop potential drugs. Dozens of childhood cancers fall in this category, some so rare that few pediatric oncologists hear about them.
Beaverton's Children's Cancer Therapy Development Institute tackles deadliest child cancers
Beyond an unmarked door into what looks like a shabby old warehouse in Old Town Beaverton, white-coated scientists are working to find ways to treat cancers that kill almost every child they afflict.
Current Research Projects
A dedicated research team
Our research team is exploring and testing state-of-the-art treatment options for the most urgent issues facing children with cancer.
Working in our own freestanding research institution allows us to act swiftly and nimbly to achieve results—bringing cost control, speed, purpose, and focus to translate effective treatments into the clinic. To get there, we perform basic science and translational research in our industrial modern lab site (a paint factory remodeled by Nike as an off-site creative space), adjacent to the Silicon Forest in Oregon.